Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;60(7):801-807.
doi: 10.1002/jcph.1641. Epub 2020 May 21.

TMPRSS2: Potential Biomarker for COVID-19 Outcomes

Jonathan D Strope  1 , Cindy H Chau PharmD  1 , William D Figg  1
Affiliations

TMPRSS2: Potential Biomarker for COVID-19 Outcomes

Jonathan D Strope et al. J Clin Pharmacol. 2020 Jul.
No abstract available

Keywords: COVID-19; SARS-CoV-2; TMPRSS2; biomarker; coronavirus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Proposed COVID‐19 treatments. Rationale for combination therapy that effectively limits viral entry and replication as well as targets systemic clinical manifestations of viral infection such as cytokine storm. Direct TMPRSS2 inhibition with camostat and nafamostat. Remdesivir, an RNA‐dependent RNA polymerase inhibitor with anti‐viral activity, targets viral replication post entry in SARS‐CoV‐2. Hydroxychloroquine (HCQ) and chloroquine (CQ) exhibit broad spectrum effects that include viral inhibition, suppression of multiple cytokines, and vascular protective effects. Some agents target cytokine release such the anti‐IL‐6 antibody tocilizumab, the anti‐human GM‐CSF monoclonal antibody lenzilumab, or the JAK1/2 inhibitor ruxolitinib. ACE2, angiotensin I–converting enzyme 2; COVID‐19, coronavirus disease 2019; GM‐CSF, granulocyte macrophage colony‐stimulating factor; IL, interleukin; JAK, Janus kinase; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2. Created using BioRender.com.
See this image and copyright information in PMC

References

    1. Garg S KL, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory‐confirmed coronavirus disease 2019 — COVID‐NET, 14 States, March 1‐30, 2020. Atlanta, GA: Centers for Disease Control and Prevention; April 8, 2020. - PMC - PubMed
    1. Hoffmann M, Kleine‐Weber H, Schroeder S, et al. SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271‐280.e8. - PMC - PubMed
    1. Chiu RW, Tang NL, Hui DS, et al. ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. Clin Chem. 2004;50(9):1683‐1686. - PMC - PubMed
    1. Chen Y, Shan K, Qian, W . Asians and other races express similar levels of and share the same genetic polymorphisms of the SARS‐CoV‐2 cell‐entry receptor [published online ahead of print 2020]. Preprints. 10.20944/preprints202002.0258.v1. - DOI
    1. Asselta R, Mantovani A, Duga S . ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID‐19 severity in Italy [published online ahead of print 2020]. Medrxiv Preprint. 10.1101/2020.03.30.20047878. - DOI - PMC - PubMed

Publication types

MeSH terms